THE VALUE OF MERCK GHI FUND
Bringing venture mentality along with the benefits of a strategic investorDIGITAL HEALTH FOCUS
- Digital Health Expertise: A team with deep expertise in digital health and healthcare operating experience
- Focused Investment Model: Providing expansion capital for existing businesses in a therapeutic and brand-agnostic manner
- Ability to Move Quickly: Streamlined investment process and autonomy to make deals
- Focus on Creating Value: Expert guidance from an experienced, entrepreneurial senior leadership team
- Venture Approach: Incented to create value for our portfolio companies
- Merck Capabilities: Access to leading science, supply chain, commercial channel, marketing and regulatory experts
- Global Reach: Connections to Merck's global operations and talent in more than 140 countries
Bill Taranto - President, GHI Fund
Bill Taranto is the President of the GHI Fund and responsible for all areas of investing. Mr. Taranto has more than 25 years of health care experience and for 13 of these years he has been focused on healthcare investing. In addition to his experience in venture investing, Mr. Taranto has more than a decade of management operations experience. Today Mr. Taranto is a member of the Merck Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also Chairman of the GHI Fund LLC Management Board. Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various venture capital, marketing, sales and business development roles. Before J&J, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.
Max Kahn - Managing Director
Max Kahn is a Managing Director and seeks opportunities in Technology Enabled Care, with a particular emphasis on solutions for Provider and Patient Engagement. Mr. Kahn currently serves as a member of the Board of Directors of Healthsense and PatientSafe Solutions. Mr. Kahn brings over twenty years of experience in health care and emerging company investing, business development, and strategy creation and implementation. Before Merck GHI, he was in the health care strategy & alliances group at Johnson & Johnson, responsible for their new business model strategies. Prior to J&J, Mr. Kahn worked in the health care and insurance practices at McKinsey & Co. and also as a health care services and health care information investment banker at Commonwealth Associates. Mr. Kahn holds an MBA from Columbia University and a BA from the University of Pennsylvania.
Joel Krikston - Managing Director
Joel Krikston is a Managing Director focused on identifying new investment opportunities in Health Information Technology and Technology Enabled Services with an emphasis on Accountable Care. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining GHI, he was an Investment Principal at Johnson & Johnson Development Corporation, leading the group's efforts in healthcare technology and diagnostics while also supporting medical devices and pharmaceuticals. During Mr. Krikston's seven years with Johnson & Johnson, he served in a range of business development roles at both the corporate and operating company level focused on the identification, formation, development and launch of new businesses in emergent healthcare segments. He also spent eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Mr. Krikston has an MBA with honors from the Stern School of Business at NYU and completed his Bachelor's degree in Finance and International Business at Fairfield University.
David Rubin - Managing Director
David M. Rubin, Ph.D., is a Managing Director focusing on opportunities in Precision Medicine and Decision Support. Dr. Rubin has spent more than 20 years in the healthcare and information industries. He holds board seats at Asuragen, Daktari Diagnostics, Electrocore, Prophecy, and Virtualscopics. Before joining the GHI team, Dr. Rubin managed Merck's efforts in MRL Oncology, including the development of franchise strategies, and portfolio valuation. David joined Merck from Cognia Corporation, a venture-backed international healthcare R&D software company, where he was CEO. Previously, Dr. Rubin was at The Wilkerson Group/IBM Global Services. Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Dave Stevenson - Managing Director
Dave Stevenson is a Managing Director and identifies opportunities in all areas of digital health, with a particular focus on Decision Support. Mr. Stevenson also manages the GHI portfolio and operations. He holds a board seat at eHealth Technologies. Mr. Stevenson brings more than 20 years of healthcare strategy and operations expertise to the GHI team. Prior to joining Merck GHI, he was part of Merck's Corporate Strategy Office working on whitespace strategies. Before joining Merck seven years ago, Mr. Stevenson was AVP of U.S. Strategy at Sanofi-Aventis responsible for development of the company's new commercial models. Before Sanofi-Aventis, he was with Ernst & Young/Capgemini as a growth strategy consultant across the healthcare industry. Mr. Stevenson started his career with Sandoz/Novartis where he built their first clinical trial management system. Mr. Stevenson holds an MBA from Vanderbilt University and a B.A. from Washington University.
Joe Volpe - Managing Director
Joe Volpe is a Managing Director responsible for identifying opportunities in Health IT, specifically in informatics, analytics and integration platforms. Mr. Volpe has more than 25 years of experience in health care investing applying a technical engineering background coupled with an understanding of emerging technologies in health care. He holds board seats with ClearDATA, Liaison Technologies, Medivo, Preventice, and Remedy Informatics. Prior to joining Merck, Mr. Volpe spent more than a decade with J&J Corporate Innovations division and strategic development group dealing with consumer, device and pharmaceutical companies developing health care strategies and investments, including physician systems, managed markets platforms, e-prescribing organizations, consumer and professional sales, and marketing. Mr. Volpe began his career as a Systems Engineer with Electronic Data Systems (EDS) working with health care insurance systems, military systems and robotics. He holds a B.S. from the University of South Florida.
President, GHI Fund